Scilex Holding Company

NASDAQ:SCLX

Drug Manufacturers - General

Healthcare
$6.34 -2.38%

-$0.17 today

Market cap
$53.83M
Beta
1.71
P/E (TTM)
-0.1
EPS (TTM)
-$60.90
52W Low $2.62High $21.34

Volume 0.00M

Average 0.13M

SCLX Pre-Tax Margin

Income before tax as a percentage of revenue.

Scilex Holding CompanyNASDAQ: SCLX

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -530.0%

Pre-tax margin was -530.0% in Q1 FY2026, down 8.8 pp from a year earlier. On a trailing-twelve-month basis it was -1162.4%, down 1015.4 pp year over year. Over 3 fiscal years it narrowed by 1174.9 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-530.0%+431.8 pp QoQ
Last fiscal yearDec 2025
-1236.3%-1107.7 pp YoY
LTMMar 2026
-1162.4%-1015.4 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-8.8 pp——
1 year-1107.7 pp——
3 years-1174.9 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1236.3%
Year-over-year change
-1107.7pp

Pre-Tax Margin vs competitors

How SCLX compares with its peers on the latest reported figures

  • SCLX's LTM Mar 2026 pre-tax margin of -1162.4% is the 7th highest of the 8 companies compared; the peer median is -747.6%.
  • Its year-over-year change of -1015.4 pp is the 6th highest of 7, against a peer median of -183.1 pp.
  • Over three fiscal years its change of -1174.9 pp compares with a peer median of -108.6 pp.
SCLX Competitors Peer median
Pre-Tax Margin for SCLX and competitors
Company Period LTM level YoY 3-year change
AGENAgenus Inc.LTM Mar 202650.5% +246.6 pp+232.6 pp
SEERSeer, Inc.LTM Mar 2026-468.0% +96.8 pp+177.7 pp
ALECAlector, Inc.LTM Mar 2026-679.9% -540.3 pp-581.0 pp
CTORCitius Oncology, Inc.LTM Mar 2026-747.6% ——
LUCDLucid Diagnostics Inc.LTM Mar 2026-876.7% +604.8 pp+13666.8 pp
IRDOpus Genetics, Inc.LTM Mar 2026-892.4% -462.9 pp-395.0 pp
SCLXScilex Holding CompanyLTM Mar 2026-1162.4% -1015.4 pp-1174.9 pp
INOInovio Pharmaceuticals, Inc.FY2025-130000.0% -80745.7 pp-127273.3 pp
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding SCLX) -747.6%-183.1 pp-108.6 pp

Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue31.32M38.03M46.74M56.59M30.25M
Cost of Revenue3.63M10.8M15.68M16.69M15.22M
Gross Profit27.68M27.24M31.06M39.9M15.03M
Gross Margin88.4%71.6%66.5%70.5%49.7%
Research & Development9.2M9.05M12.75M9.64M20.71M
Selling, General & Admin50.58M64.9M119.64M119.02M266.63M
Operating Expenses63.52M77.87M136.49M123.3M287.34M
Depreciation & Amortization3.78M4.45M4.15M4.05M4.62M
EBITDA(72.88M)(9.3M)(109.1M)(66.8M)(357.95M)
EBITDA Margin-232.7%-24.5%-233.4%-118.0%-1183.2%
Operating Income(35.84M)(50.63M)(105.43M)(83.4M)(272.3M)
Operating Margin-114.4%-133.1%-225.6%-147.4%-900.1%
Interest Income00000
Interest Expense11.76M9.6M1.07M1.96M11.46M
Other Income / Expenses(52.58M)27.27M(8.89M)10.59M(101.72M)
Income Before Tax(88.42M)(23.36M)(114.32M)(72.81M)(374.03M)
Pre-Tax Margin-282.3%-61.4%-244.6%-128.7%-1236.3%
Income Tax Expense5K4K13K(1K)26K
Net Income(88.42M)(23.36M)(114.33M)(72.81M)(358.73M)
Net Margin-282.4%-61.4%-244.6%-128.7%-1185.8%
EPS (Basic)(23.29)(6.09)(44.85)(19.43)(36.48)
EPS (Diluted)(23.29)(6.09)(44.85)(19.43)(36.48)
Weighted Avg Shares3.8M3.83M3.72M6.95M11.03M
Weighted Avg Shares (Diluted)3.8M3.83M3.72M6.95M11.03M

Scilex Holding Company

NASDAQ:SCLX

Intrinsic Alpha fair value

Locked

Current Price

$6.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.